NAD+ (nicotinamide adenine dinucleotide) is not FDA-approved as a drug. It has no approved medical indications, no standardized dosing, and no FDA-reviewed safety profile for therapeutic use. NAD+ exists in a regulatory gray area: it can be sold as a dietary supplement or used as a compounding ingredient, but it has never gone through the formal drug approval process that would give it an FDA stamp of approval for treating any condition.
How the FDA Actually Classifies NAD+
The FDA draws a hard line between drugs and dietary supplements. Drugs must prove they are safe and effective through clinical trials before reaching the market. Supplements do not. NAD+ falls on the supplement side of that line, meaning companies can sell it in oral form (capsules, powders, sublingual tablets) without FDA approval, as long as they don’t claim it treats or cures a disease.
This is an important distinction. When something is “not FDA-approved,” it doesn’t necessarily mean it’s dangerous or useless. It means no one has submitted the extensive clinical trial data the FDA requires to approve a drug, and the agency has not evaluated NAD+ for safety or effectiveness in treating any specific medical condition. The supplement industry operates under different rules: manufacturers are responsible for their own product safety, and the FDA only steps in after problems are reported.
NAD+ Precursors With FDA Recognition
While NAD+ itself isn’t approved, some of its precursors (compounds your body converts into NAD+) do have FDA recognition in various forms.
Niacin, also known as vitamin B3, is one of the few NAD+ precursors with actual FDA-approved drug indications. In prescription form, niacin is approved to treat high cholesterol and abnormal blood lipid levels. Specifically, it’s approved to lower LDL cholesterol, triglycerides, and total cholesterol while raising HDL cholesterol. It’s also approved to reduce the risk of repeat heart attacks in people with a history of high cholesterol and prior heart attacks, and to slow the progression of arterial disease when combined with other medications.
Nicotinamide riboside (NR), another popular NAD+ precursor sold under brand names like Niagen, holds a different kind of FDA status. ChromaDex, the company behind Niagen, received a “no questions” response from the FDA on its GRAS (Generally Recognized as Safe) notice in 2016. This means the FDA did not object to NR being used as a food ingredient at specific levels, with an estimated upper tolerable intake of about 180 mg per day for a 60 kg person. GRAS status is not the same as drug approval. It simply means the ingredient is considered safe to add to food products like protein shakes, nutrition bars, and vitamin waters at specified concentrations.
The Problem With NAD+ IV Therapy
NAD+ IV drips have become a popular offering at wellness clinics, marketed for everything from anti-aging to addiction recovery. This is where the regulatory picture gets concerning.
The FDA has issued warnings about compounders using food-grade NAD+ to make injectable products. Food-grade ingredients are not suitable for sterile compounding without appropriate processing, because they carry a high risk of contamination with microbes and endotoxins. The agency has received adverse event reports from people who received NAD+ injections, including severe chills, shaking, vomiting, and fatigue serious enough to require medical treatment. The FDA noted these reactions are consistent with excessive endotoxin levels, meaning the problems likely stemmed from contaminated ingredients rather than NAD+ itself.
Compounding pharmacies can legally prepare NAD+ injectable products under certain sections of federal law, but they must use pharmaceutical-grade ingredients processed for sterile use. The FDA’s concern is that some compounders are cutting corners by using cheaper food-grade NAD+ powder, creating a real safety risk for patients receiving IV infusions.
Known Side Effects of NAD+ Precursors
Because NAD+ hasn’t gone through formal drug trials, its side effect profile comes mostly from studies on its precursors, particularly nicotinamide (NAM). At moderate oral doses, side effects tend to be minor: dull headaches, nausea, and dizziness. These typically resolve once a person stops taking the supplement.
Higher doses carry more serious risks. Daily doses of 2 grams of nicotinamide for as little as two weeks have been linked to decreased insulin sensitivity and increased oxidative stress. At 3 grams per day, liver injury becomes a concern, including inflammation and bile flow problems. Long-term use at doses above 1,300 mg per day has been associated with drops in blood platelet counts and, in people with kidney disease, accumulation of a metabolite now classified as a uremic toxin.
Most of these adverse effects have been observed at doses well above what typical supplements provide, and most resolved after people stopped taking the supplement. Still, the lack of FDA oversight means supplement labels may not always reflect these risks clearly.
What This Means for Consumers
If you’re considering NAD+ supplements, the key takeaway is that you’re operating outside the FDA’s drug approval framework. No NAD+ product has been proven through FDA-reviewed clinical trials to treat aging, cognitive decline, fatigue, addiction, or any other condition it’s commonly marketed for. Oral NAD+ precursors like nicotinamide riboside have at least cleared the GRAS threshold for food safety, which provides a baseline level of reassurance at recommended doses.
IV NAD+ therapy carries additional risks because of the compounding process. If a clinic offers NAD+ drips, the safety depends heavily on whether the compounder used pharmaceutical-grade ingredients processed for sterile injection. There is currently no easy way for consumers to verify this, and the FDA has documented cases where this standard was not met.